JP2016539093A - 電磁波を利用した癌温熱治療用感作剤組成物及びこれを用いた癌治療方法 - Google Patents
電磁波を利用した癌温熱治療用感作剤組成物及びこれを用いた癌治療方法 Download PDFInfo
- Publication number
- JP2016539093A JP2016539093A JP2016524018A JP2016524018A JP2016539093A JP 2016539093 A JP2016539093 A JP 2016539093A JP 2016524018 A JP2016524018 A JP 2016524018A JP 2016524018 A JP2016524018 A JP 2016524018A JP 2016539093 A JP2016539093 A JP 2016539093A
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- treatment
- ions
- apotransferrin
- iron
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 287
- 201000011510 cancer Diseases 0.000 title claims abstract description 266
- 238000011282 treatment Methods 0.000 title claims abstract description 99
- 238000000034 method Methods 0.000 title claims abstract description 50
- 206010020843 Hyperthermia Diseases 0.000 title claims abstract description 46
- 230000036031 hyperthermia Effects 0.000 title claims abstract description 46
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 229910021645 metal ion Inorganic materials 0.000 claims abstract description 132
- 108010054176 apotransferrin Proteins 0.000 claims abstract description 72
- 238000000015 thermotherapy Methods 0.000 claims abstract description 51
- 230000001965 increasing effect Effects 0.000 claims abstract description 21
- 238000001959 radiotherapy Methods 0.000 claims abstract description 9
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 5
- 238000002512 chemotherapy Methods 0.000 claims abstract description 5
- 230000035945 sensitivity Effects 0.000 claims abstract description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N iron Substances [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 110
- 229910052742 iron Inorganic materials 0.000 claims description 75
- -1 iron ions Chemical class 0.000 claims description 53
- 239000005720 sucrose Substances 0.000 claims description 14
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 13
- 229930006000 Sucrose Natural products 0.000 claims description 13
- 229920002472 Starch Polymers 0.000 claims description 9
- 239000008107 starch Substances 0.000 claims description 9
- 235000019698 starch Nutrition 0.000 claims description 9
- NZZFEUNDIKEEJZ-UHFFFAOYSA-N 2-(hydroxymethyl)-6-[2-(3,4,5-trihydroxy-6-methoxyoxan-2-yl)ethyl]oxane-3,4,5-triol Chemical compound OC1C(O)C(O)C(OC)OC1CCC1C(O)C(O)C(O)C(CO)O1 NZZFEUNDIKEEJZ-UHFFFAOYSA-N 0.000 claims description 7
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 claims description 6
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims description 6
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 6
- 229940050410 gluconate Drugs 0.000 claims description 6
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims description 5
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 5
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 5
- 241000282412 Homo Species 0.000 claims description 5
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- 229920002307 Dextran Polymers 0.000 claims description 4
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 claims description 4
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims description 4
- 239000001913 cellulose Substances 0.000 claims description 4
- 229920002678 cellulose Polymers 0.000 claims description 4
- 230000001678 irradiating effect Effects 0.000 claims description 4
- 229910001425 magnesium ion Inorganic materials 0.000 claims description 4
- 238000002560 therapeutic procedure Methods 0.000 claims description 4
- 102000004506 Blood Proteins Human genes 0.000 claims description 3
- 108010017384 Blood Proteins Proteins 0.000 claims description 3
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 3
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 3
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 3
- 229910052782 aluminium Inorganic materials 0.000 claims description 3
- 238000001815 biotherapy Methods 0.000 claims description 3
- 229910001451 bismuth ion Inorganic materials 0.000 claims description 3
- 229910001430 chromium ion Inorganic materials 0.000 claims description 3
- 229910001431 copper ion Inorganic materials 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 238000009169 immunotherapy Methods 0.000 claims description 3
- 229910001449 indium ion Inorganic materials 0.000 claims description 3
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 claims description 3
- 229910001437 manganese ion Inorganic materials 0.000 claims description 3
- 238000002428 photodynamic therapy Methods 0.000 claims description 3
- 229910052707 ruthenium Inorganic materials 0.000 claims description 3
- 239000000600 sorbitol Substances 0.000 claims description 3
- CKHJYUSOUQDYEN-UHFFFAOYSA-N gallium(3+) Chemical compound [Ga+3] CKHJYUSOUQDYEN-UHFFFAOYSA-N 0.000 claims description 2
- OYEHPCDNVJXUIW-UHFFFAOYSA-N plutonium atom Chemical compound [Pu] OYEHPCDNVJXUIW-UHFFFAOYSA-N 0.000 claims description 2
- 230000001235 sensitizing effect Effects 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 abstract description 81
- 108090000901 Transferrin Proteins 0.000 abstract description 81
- 239000012581 transferrin Substances 0.000 abstract description 80
- 230000000694 effects Effects 0.000 abstract description 11
- 230000020169 heat generation Effects 0.000 abstract description 7
- 238000011394 anticancer treatment Methods 0.000 abstract description 3
- 210000004027 cell Anatomy 0.000 description 97
- 239000007864 aqueous solution Substances 0.000 description 24
- FWZTTZUKDVJDCM-CEJAUHOTSA-M disodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);hydroxide;trihydrate Chemical compound O.O.O.[OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[O-2].[Na+].[Na+].[Fe+3].[Fe+3].[Fe+3].[Fe+3].[Fe+3].O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FWZTTZUKDVJDCM-CEJAUHOTSA-M 0.000 description 24
- 229940032961 iron sucrose Drugs 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 24
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000008859 change Effects 0.000 description 18
- 239000012153 distilled water Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 18
- 210000004369 blood Anatomy 0.000 description 17
- 239000008280 blood Substances 0.000 description 17
- MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 102000007238 Transferrin Receptors Human genes 0.000 description 12
- 108010033576 Transferrin Receptors Proteins 0.000 description 12
- 229910052751 metal Inorganic materials 0.000 description 12
- 239000002184 metal Substances 0.000 description 12
- 230000008569 process Effects 0.000 description 12
- 238000010438 heat treatment Methods 0.000 description 11
- 239000002504 physiological saline solution Substances 0.000 description 11
- 238000011319 anticancer therapy Methods 0.000 description 9
- 238000001095 inductively coupled plasma mass spectrometry Methods 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 7
- 229960004887 ferric hydroxide Drugs 0.000 description 7
- IEECXTSVVFWGSE-UHFFFAOYSA-M iron(3+);oxygen(2-);hydroxide Chemical compound [OH-].[O-2].[Fe+3] IEECXTSVVFWGSE-UHFFFAOYSA-M 0.000 description 7
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 description 7
- 150000003839 salts Chemical class 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 6
- 239000002246 antineoplastic agent Substances 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 229910052749 magnesium Inorganic materials 0.000 description 6
- 239000011777 magnesium Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010171 animal model Methods 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 238000011717 athymic nude mouse Methods 0.000 description 5
- 230000003247 decreasing effect Effects 0.000 description 5
- 238000002651 drug therapy Methods 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- 230000001093 anti-cancer Effects 0.000 description 4
- 150000001720 carbohydrates Chemical class 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000002148 esters Chemical class 0.000 description 4
- 229960001781 ferrous sulfate Drugs 0.000 description 4
- 239000011790 ferrous sulphate Substances 0.000 description 4
- 235000003891 ferrous sulphate Nutrition 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 4
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 4
- 201000005202 lung cancer Diseases 0.000 description 4
- 208000020816 lung neoplasm Diseases 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- 238000010172 mouse model Methods 0.000 description 4
- 239000002105 nanoparticle Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- 102000008133 Iron-Binding Proteins Human genes 0.000 description 3
- 108010035210 Iron-Binding Proteins Proteins 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 108010041746 diferric transferrin Proteins 0.000 description 3
- 238000007865 diluting Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 150000002739 metals Chemical class 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000012086 standard solution Substances 0.000 description 3
- 210000002784 stomach Anatomy 0.000 description 3
- 238000001931 thermography Methods 0.000 description 3
- 238000012546 transfer Methods 0.000 description 3
- ZUGAOYSWHHGDJY-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-aluminabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Al+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O ZUGAOYSWHHGDJY-UHFFFAOYSA-K 0.000 description 2
- YEEGWNXDUZONAA-UHFFFAOYSA-K 5-hydroxy-2,8,9-trioxa-1-gallabicyclo[3.3.2]decane-3,7,10-trione Chemical compound [Ga+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O YEEGWNXDUZONAA-UHFFFAOYSA-K 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- PMVSDNDAUGGCCE-TYYBGVCCSA-L Ferrous fumarate Chemical compound [Fe+2].[O-]C(=O)\C=C\C([O-])=O PMVSDNDAUGGCCE-TYYBGVCCSA-L 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000021375 Xenogenes Species 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000005907 cancer growth Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000011773 ferrous fumarate Substances 0.000 description 2
- 235000002332 ferrous fumarate Nutrition 0.000 description 2
- 229960000225 ferrous fumarate Drugs 0.000 description 2
- 229940102709 ferumoxytol Drugs 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910001922 gold oxide Inorganic materials 0.000 description 2
- 108010045676 holotransferrin Proteins 0.000 description 2
- UCNNJGDEJXIUCC-UHFFFAOYSA-L hydroxy(oxo)iron;iron Chemical compound [Fe].O[Fe]=O.O[Fe]=O UCNNJGDEJXIUCC-UHFFFAOYSA-L 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000002082 metal nanoparticle Substances 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 231100000956 nontoxicity Toxicity 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000003868 tissue accumulation Effects 0.000 description 2
- 238000013413 tumor xenograft mouse model Methods 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- WNDUPUMWHYAJOR-SADXPQEKSA-K (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+) Chemical compound [Fe+3].OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WNDUPUMWHYAJOR-SADXPQEKSA-K 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 235000020847 Body for Life Nutrition 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Natural products OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 206010023825 Laryngeal cancer Diseases 0.000 description 1
- 108060001084 Luciferase Proteins 0.000 description 1
- 239000005089 Luciferase Substances 0.000 description 1
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- 102000010750 Metalloproteins Human genes 0.000 description 1
- 108010063312 Metalloproteins Proteins 0.000 description 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 229910052778 Plutonium Inorganic materials 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- LCKIEQZJEYYRIY-UHFFFAOYSA-N Titanium ion Chemical compound [Ti+4] LCKIEQZJEYYRIY-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124650 anti-cancer therapies Drugs 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000004611 cancer cell death Effects 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 239000005515 coenzyme Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 229940057538 ferric acetyl transferrin Drugs 0.000 description 1
- 229960002413 ferric citrate Drugs 0.000 description 1
- 229940042644 ferrlecit Drugs 0.000 description 1
- 229960002089 ferrous chloride Drugs 0.000 description 1
- 239000004222 ferrous gluconate Substances 0.000 description 1
- 235000013924 ferrous gluconate Nutrition 0.000 description 1
- 229960001645 ferrous gluconate Drugs 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 229910052733 gallium Inorganic materials 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 150000002505 iron Chemical class 0.000 description 1
- NMCUIPGRVMDVDB-UHFFFAOYSA-L iron dichloride Chemical compound Cl[Fe]Cl NMCUIPGRVMDVDB-UHFFFAOYSA-L 0.000 description 1
- 229940096010 iron polysaccharide Drugs 0.000 description 1
- NPFOYSMITVOQOS-UHFFFAOYSA-K iron(III) citrate Chemical compound [Fe+3].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NPFOYSMITVOQOS-UHFFFAOYSA-K 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 150000002736 metal compounds Chemical class 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- MHHDXUNFNAZUGB-UHFFFAOYSA-N oxidovanadium(2+) Chemical compound [V+2]=O MHHDXUNFNAZUGB-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940062350 sodium ferric gluconate complex Drugs 0.000 description 1
- MQBDAEHWGRMADS-XNHLMZCASA-M sodium;(2r,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;iron(3+);oxygen(2-);(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoate Chemical compound [O-2].[O-2].[O-2].[Na+].[Fe+3].[Fe+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1.O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 MQBDAEHWGRMADS-XNHLMZCASA-M 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000001331 thermoregulatory effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 125000005287 vanadyl group Chemical group 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0052—Thermotherapy; Hyperthermia; Magnetic induction; Induction heating therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/40—Transferrins, e.g. lactoferrins, ovotransferrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/02—Radiation therapy using microwaves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N5/0613—Apparatus adapted for a specific treatment
- A61N5/062—Photodynamic therapy, i.e. excitation of an agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0661—Radiation therapy using light characterised by the wavelength of light used ultraviolet
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
- A61N2005/1092—Details
- A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Radiation-Therapy Devices (AREA)
Abstract
Description
人体に摂取される経口用または注射剤用金属イオンは、塩に結合された結合物の形態であるか、或いは炭水化物(carbohydrate)またはタンパク質といった高分子と結合された結合物の形態である。金属イオンと結合される塩としては、クエン酸塩(citrate)、塩化物(chloride)、硫酸塩(sulfate)、フマル酸塩(fumarate)などを例示することができ、これによる結合物としては、硫酸第一鉄(ferrous sulfate)、フマル酸第一鉄(ferrous fumarate)、グルコン酸第一鉄(ferrous gluconate)などを例示することができる。
金属イオンのアポトランスフェリン結合能を評価するために、鉄イオン(ferric iron、Fe III+)の濃度に応じてトランスフェリン結合能(Unsaturated Iron−Binding Capacity、UIBC)を次のとおり測定した。
「金属イオンが非共有結合されたアポトランスフェリン」(トランスフェリン)の発熱能を評価するために、鉄が結合されていないアポトランスフェリン、及び、鉄が結合されているアポトランスフェリンの水溶液に電磁波処理を行なった後、温度を測定した。鉄イオンが結合されていないアポトランスフェリン(Sigma Aldrich、USA)の水溶液を0、0.04、0.2、1、5mg/mlの濃度に希釈した後、各濃度ごとに0.1mlを96ウェルプレートに分注して準備した。
金属イオンが非共有結合されたアポトランスフェリンによる温度上昇能をin vitroの細胞実験で評価した。トランスフェリン受容体が過剰発現されている癌細胞株NCI−H460(Califer Life Sciences)を培養した後、濃度1×103cells/mlの細胞懸濁液0.1mlを96ウェルプレートに分注し、37℃のCO2培養器で12時間培養した。また、対照群としてヒト正常細胞のストロマ細胞(stromal cell)を培養して濃度3×103cells/mlの0.1mlを96ウェルプレートに分注し、37℃のCO2培養器で12時間培養した。
金属イオンの投与時に実際に癌組織に蓄積されるかをin vivo動物実験で評価するために、まず、癌移植(tumor xenograft)動物モデルを次のとおり作製した。肺癌細胞株NCI−H460−luc2(Califer Life Sciences)を培養した後、5×106の細胞を6〜8週齢の雌BALB/c無胸腺ヌードマウス(athymic nude mouse)(ダムルサイエンス製)の皮下に注射した後、10日程度育てることで、癌組織が100mm3以上成長するようにして癌移植(tumor xenograft)動物モデルを作製した。
「金属イオンが非共有結合されたアポトランスフェリン」(トランスフェリン)の癌組織蓄積能を評価するために、鉄が結合されているトランスフェリンの水溶液をマウスに投与した後、正常組織と癌組織における金属イオンの濃度を測定した。鉄イオンが結合されたアポトランスフェリン(トランスフェリン)の水溶液を4mg/mlにて準備した後、16mg/kgの用量で0.1ml静脈注射した。24時間経過の後、実験例5と同様の方法で各組織を採取し、金属イオンの濃度をICP−MS(Inductively coupled plasma mass spectrometry;Varian 800−MS、Palo Alto、US)で測定した。
癌細胞は、非正常な分裂を継続すべく、急速な細胞分裂に必要な栄養成分を急激に受け入れるが、代謝調節能が低い。実際、癌細胞は、トランスフェリン受容体を過剰発現させ、細胞分裂に必要な鉄を多く受け入れるが、熱調節能に劣り、正常細胞に比べて高熱に、相対的に敏感であることが知られている。したがって、癌細胞にのみ集中的に熱を加えると、癌細胞の選択的死滅が可能である。癌細胞に対する標的指向性を有するトランスフェリンは、癌細胞に過剰発現されたトランスフェリン受容体を介して癌細胞に鉄を集中的に伝達するが、この際、癌細胞に電磁波処理を行なう際の温度上昇による癌細胞死滅が可能であろうと予測された。
Claims (12)
- 電磁波を利用した癌温熱治療用の感作剤組成物。
- 前記感作剤は、金属イオン、金属イオン結合物、金属イオンが非共有結合されたアポトランスフェリン、および金属イオンが非共有結合されたアポトランスフェリン誘導体よりなる群から選択されることを特徴とする、請求項1に記載の電磁波を利用した癌温熱治療用感作剤組成物。
- 前記金属イオンは、鉄(iron)イオン、マンガン(manganese)イオン、亜鉛(zinc)イオン、銅(copper)イオン、マグネシウム(magnesium)イオン、ビスマス(bismuth)イオン、ルテニウム(ruthenium)イオン、チタン(titanium)イオン、ガリウム(gallium)イオン、インジウム(indium)イオン、バナジル(vanadyl)イオン、クロム(chromium)イオン、アルミニウム(aluminum)イオン、およびプルトニウム(plutonium)イオンよりなる群から選択されることを特徴とする、請求項2に記載の癌温熱治療用感作剤組成物。
- 前記金属イオン結合物は、金属イオンにデキストラン(dextran)、スクロース(sucrose)、グルコナート(gluconate)、ソルビトール(sorbitol)、多糖類(polysaccharide)、カルボキシマルトース(carboxymaltose)、フェルモキシトール(ferumoxytol)、イソマルトシド(isomaltoside)、シトラート(citrate)、塩化物(chloride)、スルファート(sulfate)、フマラート(fumarate)、マルトース(maltose)、デンプン(starch)、セルロース(cellulose)、およびアルブミン(albumin)を含む群から選択される結合物が非共有結合していることを特徴とする、請求項2に記載の癌温熱治療用感作剤組成物。
- 前記アポトランスフェリンまたはアポトランスフェリン誘導体は、ヒトまたは哺乳動物由来の血清タンパク質であるか、或いは組換えタンパク質であることを特徴とする、請求項2に記載の癌温熱治療用感作剤組成物。
- 前記感作剤は0.01〜100mg/mlの濃度であることを特徴とする、請求項1に記載の癌温熱治療用感作剤組成物。
- 薬学的に許容される担体をさらに含むことを特徴とする、請求項1に記載の癌温熱治療用感作剤組成物。
- 請求項1に記載の電磁波を利用した癌温熱治療用感作剤組成物、および電磁波を照射する装置を含む、癌温熱治療用キット。
- (a)ヒトを除く動物に請求項1に記載の癌温熱治療用感作剤組成物を投与して癌治療に対する感受性を増加させる段階と、
(b)電磁波処理を行う段階とを含んでなることを特徴とする、癌治療方法。 - 前記癌温熱治療用感作剤組成物が金属イオンまたは金属イオン結合物である場合には、0.1〜50mg/kgの用量で投与し、金属イオンが非共有結合されたアポトランスフェリンまたはその誘導体である場合には0.1〜200mg/kgの用量で投与することを特徴とする、請求項9に記載の癌治療方法。
- 前記電磁波は、ガンマ線、X線、紫外線、可視光線、赤外線、マイクロ波、およびラジオ電波よりなる群から選択されることを特徴とする、請求項9に記載の癌治療方法。
- 化学療法(chemotherapy)、放射線療法(radiation therapy)、生物学的療法(biological therapy)、免疫療法(immunotherapy)および光線力学的療法(photodynamic therapy)よりなる群から選択される1種以上の治療方法を並行することを特徴とする、請求項9に記載の癌治療方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2013-0123051 | 2013-10-16 | ||
KR20130123051 | 2013-10-16 | ||
KR1020140109008A KR101536325B1 (ko) | 2013-10-16 | 2014-08-21 | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 |
KR10-2014-0109008 | 2014-08-21 | ||
PCT/KR2014/009641 WO2015056960A1 (ko) | 2013-10-16 | 2014-10-14 | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2016539093A true JP2016539093A (ja) | 2016-12-15 |
JP6404920B2 JP6404920B2 (ja) | 2018-10-17 |
Family
ID=53037025
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2016524018A Active JP6404920B2 (ja) | 2013-10-16 | 2014-10-14 | 電磁波を利用した癌温熱治療用感作剤組成物及びこれを用いた癌治療方法 |
Country Status (7)
Country | Link |
---|---|
US (3) | US20160310594A1 (ja) |
EP (1) | EP3058949B1 (ja) |
JP (1) | JP6404920B2 (ja) |
KR (1) | KR101536325B1 (ja) |
CN (1) | CN105682677B (ja) |
CA (1) | CA2927528C (ja) |
RU (1) | RU2016118565A (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2016379439B2 (en) * | 2015-12-23 | 2021-07-22 | Brown University | Thermal accelerant compositions and methods of use |
CN107184979B (zh) * | 2017-05-15 | 2020-09-29 | 西南民族大学 | 具有微波增敏及核磁成像功能的铜锌锡硫四元纳米复合材料及其制备与应用方法 |
CN108525128B (zh) * | 2018-03-26 | 2021-02-12 | 清华大学 | 液态金属作为肿瘤磁热疗介质的应用 |
EP3906058A4 (en) * | 2019-01-03 | 2022-02-16 | Synergymed Devices Inc. | ACCURATE ABLATION TREATMENT OF CANCER USING SYNERGETIC EFFECTS OF ELECTROMAGNETIC RADIATION WITH NANOPARTICLES |
CN113189189A (zh) * | 2021-04-01 | 2021-07-30 | 亚宝药业四川制药有限公司 | 药物检测方法及复方葡萄糖酸钙口服溶液的质量控制方法 |
KR102378498B1 (ko) * | 2021-05-26 | 2022-03-29 | 주식회사 칼라세븐 | 피부 접착식 광선조사기의 사용 방법 |
CN114558148B (zh) * | 2022-03-18 | 2024-03-08 | 郑州大学 | 一种肿瘤“开关型”纳米光疗系统的制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01235851A (ja) * | 1983-02-08 | 1989-09-20 | Schering Ag | 診断および疾病治療用組成物 |
JP2006298897A (ja) * | 2005-03-25 | 2006-11-02 | Nipro Corp | 放射線増感剤 |
JP2009233175A (ja) * | 2008-03-27 | 2009-10-15 | Tottori Univ | 生体内温熱療法及び閉塞下動注化学療法を併用した新規治療方法に用いるバルーンカテーテル |
JP2011520791A (ja) * | 2008-05-02 | 2011-07-21 | アイティーアイ・スコットランド・リミテッド | 医療において用いるためのベクター |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4569836A (en) * | 1981-08-27 | 1986-02-11 | Gordon Robert T | Cancer treatment by intracellular hyperthermia |
GB0313259D0 (en) | 2003-06-09 | 2003-07-16 | Consejo Superior Investigacion | Magnetic nanoparticles |
US20060217291A1 (en) * | 2005-03-25 | 2006-09-28 | Ichiro Hirotsu | Radiosensitizer |
KR20140117678A (ko) * | 2006-01-06 | 2014-10-07 | 루이트폴드 파머수티컬스, 인코퍼레이티드 | 철을 투여하기 위한 방법 및 조성물 |
KR100802139B1 (ko) * | 2006-08-08 | 2008-02-11 | 한국생명공학연구원 | 자성 나노입자를 함유하는 골드 나노케이지 |
WO2008140831A2 (en) * | 2007-01-18 | 2008-11-20 | Trustees Of Dartmouth College | Iron/iron oxide nanoparticle and use thereof |
US20110104073A1 (en) | 2007-01-18 | 2011-05-05 | Qi Zeng | Iron/Iron Oxide Nanoparticle and Use Thereof |
US9358292B2 (en) * | 2007-04-08 | 2016-06-07 | Immunolight, Llc | Methods and systems for treating cell proliferation disorders |
US20090181048A1 (en) * | 2007-06-08 | 2009-07-16 | The Regents Of The University Of California | Cancer drug delivery using modified transferrin |
ES2320837B1 (es) | 2007-07-26 | 2010-03-04 | Consejo Superior De Investigaciones Cientificas | Dispositivo de hipertermia y su utilizacion con nanoparticulas. |
US20110052672A1 (en) * | 2008-01-16 | 2011-03-03 | Sunil Krishnan | Treatments of disease or disorders using nanoparticles for focused hyperthermia to increase therapy efficacy |
JP2009234923A (ja) * | 2008-03-25 | 2009-10-15 | Toda Kogyo Corp | 温熱治療用感磁性発熱体及び治療用製剤 |
KR101095396B1 (ko) * | 2009-09-17 | 2011-12-16 | 성균관대학교산학협력단 | 암 표적지향형 트랜스페린-폴리에틸렌 글리콜이 수식된 트레일, 이의 제조 및 용도 |
EP2531173B1 (en) * | 2010-02-03 | 2018-09-26 | Oncbiomune, L.L.C. | Taxane- and taxoid-protein compositions |
US9844656B2 (en) * | 2010-03-01 | 2017-12-19 | The Regents Of The University Of California | Localization of agents at a target site with a composition and an energy source |
US9012502B2 (en) | 2010-09-14 | 2015-04-21 | Sbi Pharmaceuticals Co., Ltd. | Cancer heat therapy-enhancing agent |
WO2012177875A1 (en) | 2011-06-21 | 2012-12-27 | Lockheed Martin Corporation | Direct magnetic imaging and thermal ablation for cancer diagnosis and treatment |
US20130336897A1 (en) * | 2012-06-18 | 2013-12-19 | Gerald L. Wolf | Theranosis of macrophage-associated diseases with ultrasmall superparamagnetic iron oxide nanoparticles (uspio) |
-
2014
- 2014-08-21 KR KR1020140109008A patent/KR101536325B1/ko active IP Right Grant
- 2014-10-14 EP EP14853591.7A patent/EP3058949B1/en active Active
- 2014-10-14 CN CN201480057376.4A patent/CN105682677B/zh active Active
- 2014-10-14 US US15/029,726 patent/US20160310594A1/en not_active Abandoned
- 2014-10-14 RU RU2016118565A patent/RU2016118565A/ru not_active Application Discontinuation
- 2014-10-14 CA CA2927528A patent/CA2927528C/en active Active
- 2014-10-14 JP JP2016524018A patent/JP6404920B2/ja active Active
-
2021
- 2021-03-31 US US17/219,479 patent/US20210236637A1/en not_active Abandoned
-
2022
- 2022-11-04 US US17/981,080 patent/US11752210B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH01235851A (ja) * | 1983-02-08 | 1989-09-20 | Schering Ag | 診断および疾病治療用組成物 |
JP2006298897A (ja) * | 2005-03-25 | 2006-11-02 | Nipro Corp | 放射線増感剤 |
JP2009233175A (ja) * | 2008-03-27 | 2009-10-15 | Tottori Univ | 生体内温熱療法及び閉塞下動注化学療法を併用した新規治療方法に用いるバルーンカテーテル |
JP2011520791A (ja) * | 2008-05-02 | 2011-07-21 | アイティーアイ・スコットランド・リミテッド | 医療において用いるためのベクター |
Also Published As
Publication number | Publication date |
---|---|
KR20150044796A (ko) | 2015-04-27 |
US20160310594A1 (en) | 2016-10-27 |
EP3058949A4 (en) | 2017-08-02 |
EP3058949A1 (en) | 2016-08-24 |
US11752210B2 (en) | 2023-09-12 |
US20230079782A1 (en) | 2023-03-16 |
CN105682677B (zh) | 2019-09-24 |
CA2927528C (en) | 2019-09-24 |
EP3058949B1 (en) | 2020-12-09 |
CN105682677A (zh) | 2016-06-15 |
JP6404920B2 (ja) | 2018-10-17 |
US20210236637A1 (en) | 2021-08-05 |
KR101536325B1 (ko) | 2015-07-14 |
RU2016118565A (ru) | 2017-11-20 |
CA2927528A1 (en) | 2015-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6404920B2 (ja) | 電磁波を利用した癌温熱治療用感作剤組成物及びこれを用いた癌治療方法 | |
Tabish et al. | Developing the next generation of graphene-based platforms for cancer therapeutics: The potential role of reactive oxygen species | |
Alphandery et al. | Chains of magnetosomes extracted from AMB-1 magnetotactic bacteria for application in alternative magnetic field cancer therapy | |
Ma et al. | Indocyanine green-based theranostic nanoplatform for NIR fluorescence image-guided chemo/photothermal therapy of cervical cancer | |
CN107899013B (zh) | 一种具有光动力学治疗开关效应及分子识别作用的介孔二氧化锰纳米载药系统的制备方法 | |
US20230390394A1 (en) | Bismuth-Gadolinium Nanoparticles | |
JP2008522666A (ja) | 癌のためのmriガイド下光線力学的療法 | |
Gao et al. | Targeted delivery of Bi2Se3 Nanoflowers to orthotopic liver tumor via transarterial infusion for enhanced microwave ablation sensibilization | |
US10335608B2 (en) | Photodynamic compounds and methods for activating them using ionizing radiation and/or other electromagnetic radiation for therapy and/or diagnostics | |
Huang et al. | Laser-Induced Combinatorial Chemotherapeutic, Chemodynamic, and Photothermal Therapy for Hepatocellular Carcinoma Based on Oxaliplatin-Loaded Metal–Organic Frameworks | |
Zuo et al. | Biomimetic nanovesicle with mitochondria-synthesized sonosensitizer and mitophagy inhibition for cancer sono-immunotherapy | |
CN113993554A (zh) | 选自食道、咽喉、肺、脑和肠的癌症的靶向化合物 | |
CN117677405A (zh) | 具有较高吸收率的靶向系统 | |
Bai et al. | A Silver‐Induced Absorption Red‐Shifted Dual‐Targeted Nanodiagnosis‐Treatment Agent for NIR‐II Photoacoustic Imaging‐Guided Photothermal and ROS Simultaneously Enhanced Immune Checkpoint Blockade Antitumor Therapy | |
CN111514293A (zh) | 近红外无重原子氟硼吡咯在光动力治疗转移瘤及上转换中的应用 | |
JP6940979B2 (ja) | 超音波増感剤 | |
CN107903258B (zh) | 一种脂溶性光敏剂及其制备方法和应用 | |
WO2015056960A1 (ko) | 전자기파를 이용한 암 온열치료용 감작제 조성물 및 이를 이용한 암 치료 방법 | |
CN105431199B (zh) | 局部光动力疗法 | |
US20220296709A1 (en) | Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents | |
Bai et al. | Self-sufficient nanoparticles with dual-enzyme activity trigger radical storms and activate cascade-amplified antitumor immunologic responses | |
Li et al. | Tantalum-carbon-integrated | |
RU2783177C2 (ru) | Неоадъювантная терапия для рака мочевого пузыря | |
CN114931563A (zh) | 一种透明质酸纳米颗粒/维替泊芬复合物的制备方法 | |
CN116096425A (zh) | 复合体和光免疫疗法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161220 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170317 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170502 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170619 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170919 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171215 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180214 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180314 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180828 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180913 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6404920 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |